Jubilant Life Sciences Ltd share price today (on 1 October 2023).

We Provide Best stock tips for Jubilant Life Sciences Ltd . A1 Intraday Tips is accurate share tips Provider Company in India in Nse market. A1 Intraday Tips, also provide Daily Charts with Nse Share Market current price of Jubilant Life Sciences Ltd with today performance in nse market. Contact Us for Jackpot Stock tips.

Get Free Stock Tips for Jubilant Life Sciences Ltd

In 1978, incorporated as Vam Organic Chemicals Ltd., Jubilant Organosys is a collaborative, innovative provider of products and services to the global life sciences industry, striving to accelerate the process of pharmaceutical drug approval.Jubilant Organosys Limited (JOL) is an integrated pharmaceutical industry player having presence across the pharmaceuticals value chain. The Company was incorporated in 21st June of the year 1978, JOL are a collaborative and innovative provider of products and services to the global life sciences industry, striving to accelerate the process of pharmaceutical drug approval. The Company's range of offerings include drug discovery and development services, custom research and manufacturing services, advance intermediates, fine chemicals, active pharmaceutical ingredients, dosage forms and regulatory affairs services. Its business is organized in three business segments, namely Pharmaceuticals & Life Science Products, Industrial Products and Performance Polymers.
These businesses offer products and services to meet the demands of the Pharmaceuticals, Agrochemicals, Construction, Food & Beverages, Textile, Tyres and Paper & Packaging industries. JOL's manufacturing locations in India situated at Gajraula (in Uttar Pradesh), Nanjangud (in Karnataka), Nira (in Maharashtra) and Samlaya (in Gujarat) and a US FDA approved manufacturing facility for dosage forms in Maryland, USA. The Company was tapped capital market in the year 1981 by the way of its Initial Public Offering (IPO). During the year 1983, the company's commercial production of Vinyl Acetate Monomer (VAM was started to enhance the value of the company. Research & Development center of the company got recognition from Government of India in the year 1985. JOL had introduced new products in Performance Chemicals segments during the period of 1987, Poly vinyl acetate emulsion for paint, textile, paper & packaging and woodworking industry. In 1988, the company had launched its first branded product under the name of Vamicol, an adhesive product. The plant for Pyridine & Picoline was started in the year 1990 and also the company received an ISO 9001 certification for its well known quality systems in the year 1995.
During the year 1997, the first Multi-purpose fine chemicals plant was gone to stream and also the plant for food polymer was commissioned. After a year, in 1998, JOL had entered into high value-added Pyridine derivates, commissioned Pyridine HBR and Cyano Pyridine plants. Also in the same year, the company had formed marketing subsidiary in the USA and acquired acetyl plant in western India. The Company had penetrated the Bio / chemo informatics arena by setting up Jubilant Biosys Ltd in the year 2000. During the year 2001, the company had changed its corporate and business profile, due to this; the new corporate identity was born as Jubilant Organosys Ltd. JOL had acquired the Active Pharmaceutical Ingredients (API) business in the period of 2002. The new state-of-the-art Research & Development Centre of the company in Noida, near New Delhi was established in the year 2003 with all latest scientific instruments. The Company bagged Golden Peacock award for Innovation Management for the year 2003. During the year 2004, JOL had set up medicinal chemistry services business through wholly owned subsidiary Jubilant Chemsys Ltd and also entered into formulations & regulatory affairs businesses by acquiring Pharmaceuticals Services. In the same year the company had incorporated, N.V. and PSI Supply N.V., the pharmaceutical companies in Europe.
JOL had received C Acharya Award for Development of Indigenous Technology from ICMA for the year 2004. JOL had acquired the Target Research Associates, Inc in the year of 2005 and renamed Clinsys Inc.; a US based Clinical Research Organisation (CRO). Also in the same year, the company had acquired Trinity Laboratories, Inc. and its wholly owned subsidiary, Trigen Laboratories, Inc., renamed Jubilant Pharmaceuticals, Inc., a generic pharmaceutical company in USA having a US FDA approved formulations manufacturing facility. JOL had embarked into Clinsys business by setting up wholly owned subsidiary under the name and style of Jubilant Clinsys Ltd. Jubilant's state-of-the-art Drug Discovery facility was inaugurated in Bangalore during November of the year 2006, the largest of its kind in India for providing integrated Drug Discovery solutions. As of June 2007, JOL had completed the largest overseas acquisition in Contract Manufacturing by an Indian company, through its purchase of Hollister-Stier Laboratories (Hollister). A multi million dollar long term agreement was signed with Syngenta in September of the year 2007 for the supply of Pyridines.
In December of the year 2007, the company and Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc had entered into a collaboration agreement through Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd to discover small molecule drug candidates for a novel metabolic disorders target. JOL had completed the transaction effective May of the year 2008, to acquire Canada based Draxis Speciality Pharmaceuticals Inc. (Draxis) for US$ 253 million and also in the same month of the same year, the company had acquired Speciality Molecules Pvt. Ltd., a niche manufacturer of Speciality Intermediates with manufacturing facilities located in Ambarnath (near Mumbai) in India for Rs. 199.5 million. The Company and Amgen Inc, Thousand Oaks, California, the largest US based Biotech Company, made a drug discovery partnership in July of the year 2008 through Jubilant Biosys Ltd subsidiary of Jubilant Organosys, under which Amgen and Jubilant collaborate to develop a portfolio of novel drugs in new target areas of interest across multiple therapeutic areas.
According to the Consolidated - Audited financial statement for the Year of 2012, total net operating revenues increased with 19.32%, from INR 3,455.19 tens of millions to INR 4,122.65 tens of millions. Operating result increased from INR 520.49 tens of millions to INR 873.42 tens of millions which means 67.81% change. The results of the period increased 73.56% reaching INR 394.37 tens of millions at the end of the period against INR 227.23 tens of millions last year. Return on equity (Net income/Total equity) went from 10.44% to 16.90%, the Return On Asset (Net income / Total Asset) went from 3.02% to 6.85% and the Net Profit Margin (Net Income/Net Sales) went from 6.58% to 9.57% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 236.32% compared to 247.70% of last year.